# Jade Biosciences, Inc. (JBIO)

> Source: Nexqual · https://nexqual.com/JBIO · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Jade Biosciences, Inc. (JBIO), nexqual.com/JBIO" · informational, not investment advice.

**Price:** USD 14.24 (-2.40% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 14.59 · day 14.16–14.93 · 52w 8.36–28 · market cap $906M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 50.13 (range 40–77).
- Total return with dividends: 1Y +48.1% vs S&P 500 +14.8%; 5Y -97.4% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.79, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: USD 0 paid over the last 12 months.
- Short interest: 21.57% of float (as of 2026-10-15), 10.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$114M | -$165M |
| Net income | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127M | -$153M |
| EPS (diluted) | -$65.45 | -$73.50 | -$100.45 | -$85.40 | -$3.19 | — |
| Free cash flow | -$27.6M | -$39.3M | -$56.9M | — | -$94.9M | — |
| Cash + short-term investments | $167M | $129M | $122M | $78.6M | $336M | — |
| Total debt | — | — | — | $108M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.1x · Earnings yield -16.92%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 50.13 (low 40, high 77).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-27 | BTIG | Reiterated | Buy | $77 |
| 2026-10-01 | Wedbush | Reiterated | Outperform | $47 |
| 2026-10-01 | HC Wainwright & Co. | Reiterated | Buy | $55 |
| 2026-08-11 | Wedbush | Target raised | Outperform | $45 → $47 |
| 2026-08-10 | BTIG | Target raised | Buy | $74 → $77 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +48.1% | -97.4% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +48.5% | -51.6% |
| Volatility (annualized) | 71.7% | 169.5% |
| Max drawdown | -50.1% (Apr 2026→Oct 2026) | -99.3% (Mar 2024→Jun 2025) |

## Dividends
Dividend. Paid over the last 12 months: USD 0.00 in 0 payments.
payment date: Apr 28, 2025. To receive a dividend, shares must be owned before the ex-dividend date.
| Ex-dividend date | Amount per share |
|---|---|
| 2025-04-29 | USD 2.40 |
Total by calendar year: 2025 USD 2.40.

## Short interest
11,210,801 shares sold short, 21.57% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 10,982,905 shares (+2.1%). Days to cover: 10.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/JBIO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.79 | $-0.57 | −$0.22 | $0 | 1 |
| Next quarter (ends 2026-12-31) | $-0.81 | $-0.60 | −$0.21 | $0 | 1 |
| Current fiscal year (ends 2026-12-31) | $-2.93 | $-2.28 | −$0.65 | $0 | 1 |
| Next fiscal year (ends 2027-12-31) | $-2.66 | $-2.28 | −$0.38 | $0 | 1 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-12): ±75.8%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 95.5% | ±75.8% |
| 2027-02-19 | 113 | 77.2% | ±35.1% |
| 2027-05-21 | 204 | 73.3% | ±44.4% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.76 | −$0.54 | Miss −40.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.57 | −$0.48 | Miss −18.8% | — |
| — | Quarter ended Sep 30, 2025 | −$0.48 | −$0.67 | Beat +28.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).